This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Pantethine is a naturally occurring compound derived from panthothenic acid. It acts as an intermediate in endogenous coenzyme A synthesis and is used as a dietary supplement to treat hypertriglyceridemia.
- Generic Name
- Pantethine
- DrugBank Accession Number
- DB11190
- Background
Pantethine is a naturally occurring compound synthesized in the body from pantothenic acid (vitamin B5) via addition of cysteamine. It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A. Coenzyme A plays an essential role as a cofactor in the metabolism of lipids and carbohydrates including fatty acid oxidation, carbohydrate metabolism, pyruvate degradation, and amino acid catabolism 2. Pantethine is available as a dietary supplement for lowering blood cholesterol and triglycerides.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Pantethine (DB11190)
- Weight
- Average: 554.721
Monoisotopic: 554.24440572 - Chemical Formula
- C22H42N4O8S2
- Synonyms
- Bis(pantothenamidoethyl) disulfide
- D-Bis(N-pantothenyl-beta-aminoethyl) disulfide
- D-pantethine
- Pantethine
- Pantetina
- Pantomin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Hypertriglyceridemias •••••••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Puralor Pantethine (2.5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphocholine (5 mg/1) + 1-(c14-c18 esteroyl)-2-docosahexanoyl-sn-glycero-3-phosphoethanolamine (2.5 mg/1) + Acetylcysteine amide (5 mg/1) + Ascorbic acid (25 mg/1) + Cholecalciferol (100 [iU]/1) + Citric acid (1.6 mg/1) + Cobamamide (2 mg/1) + Egg phospholipids (42.5 mg/1) + Folic acid (42.5 mg/1) + Gastric intrinsic factor (2.5 mg/1) + Magnesium L-threonate (2.5 mg/1) + Leucovorin (3 mg/1) + Levomefolic acid (0.4 mg/1) + Magnesium glycinate (1 mg/1) + Niacin (0.5 mg/1) + Papain (20 mg/1) + Riboflavin (0.5 mg/1) + Sodium citrate (0.8 mg/1) + Thiamine chloride (0.5 mg/1) Tablet, chewable Oral Centurion Labs 2014-01-01 2017-09-20 US 
Categories
- ATC Codes
- A11HA32 — Pantethine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Beta amino acids and derivatives
- Alternative Parents
- N-acyl amines / Monosaccharides / Secondary carboxylic acid amides / Secondary alcohols / Dialkyldisulfides / Sulfenyl compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides show 2 more
- Substituents
- Alcohol / Aliphatic acyclic compound / Beta amino acid or derivatives / Carbonyl group / Carboxamide group / Dialkyldisulfide / Fatty acyl / Fatty amide / Hydrocarbon derivative / Monosaccharide show 13 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- organic disulfide (CHEBI:31959)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7K81IL792L
- CAS number
- 16816-67-4
- InChI Key
- DJWYOLJPSHDSAL-ROUUACIJSA-N
- InChI
- InChI=1S/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17-18,27-28,31-32H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)(H,26,34)/t17-,18-/m0/s1
- IUPAC Name
- (2R)-N-[2-({2-[(2-{3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanamido}ethyl)disulfanyl]ethyl}carbamoyl)ethyl]-2,4-dihydroxy-3,3-dimethylbutanamide
- SMILES
- CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO
References
- General References
- Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T: Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014 Feb 27;10:89-100. doi: 10.2147/VHRM.S57116. eCollection 2014. [Article]
- Horvath Z, Vecsei L: Current medical aspects of pantethine. Ideggyogy Sz. 2009 Jul 30;62(7-8):220-9. [Article]
- External Links
- Human Metabolome Database
- HMDB0003828
- KEGG Drug
- D01234
- KEGG Compound
- C12661
- PubChem Compound
- 452306
- PubChem Substance
- 347827940
- ChemSpider
- 398402
- 32863
- ChEBI
- 31959
- ChEMBL
- CHEMBL2104786
- ZINC
- ZINC000003874604
- Wikipedia
- Pantethine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Hyperlipoproteinemia (a) 1 somestatus stop reason just information to hide 2 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome Caused by COVID-19 / Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Tablet, chewable Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.117 mg/mL ALOGPS logP -0.25 ALOGPS logP -3.4 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 12.38 Chemaxon pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 197.32 Å2 Chemaxon Rotatable Bond Count 19 Chemaxon Refractivity 139.83 m3·mol-1 Chemaxon Polarizability 59.42 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 209.3810944 predictedDarkChem Lite v0.1.0 [M-H]- 233.7560944 predictedDarkChem Lite v0.1.0 [M-H]- 215.53885 predictedDeepCCS 1.0 (2019) [M+H]+ 210.0387944 predictedDarkChem Lite v0.1.0 [M+H]+ 229.0530944 predictedDarkChem Lite v0.1.0 [M+H]+ 217.89685 predictedDeepCCS 1.0 (2019) [M+Na]+ 222.2208944 predictedDarkChem Lite v0.1.0 [M+Na]+ 230.9270944 predictedDarkChem Lite v0.1.0 [M+Na]+ 223.99 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at May 21, 2021 10:21